Eli Lilly hikes price of diabetes drug Mounjaro in UK
Digest more
Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven platform.
Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback is a buy-the-dip opportunity.
On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and Company (NYSE:LLY) with a $1,100 price target. This target boost follows the company’s Q2 results.
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.
Eli Lilly (LLY) stock recovers as company executives seize a rare buying opportunity to make a series of insider purchases following a sharp selloff. Read more here.
Eli Lilly partners with the Indiana Fever and YMCA to empower girls in basketball, removing barriers and promoting community engagement in sports.
Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise
Eli Lilly is eligible for 100M in tax credits to expand its Pleasant Prairie facility, adding 750 jobs and boosting Wisconsin s biotech manufacturing sector.
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Click here to read an analysis of LLY stock now.
Feedback